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Emergence of novel variants of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) underscores the need for
next-generation vaccines able to elicit broad and durable immunity.
Here we report the evaluation of a ferritin nanoparticle vaccine
displaying the receptor-binding domain of the SARS-CoV-2 spike
protein (RFN) adjuvanted with Army Liposomal Formulation QS-21
(ALFQ). RFN vaccination of macaques using a two-dose regimen
resulted in robust, predominantly Th1 CD4+ T cell responses and
reciprocal peak mean serum neutralizing antibody titers of 14,000
to 21,000. Rapid control of viral replication was achieved in the up-
per and lower airways of animals after high-dose SARS-CoV-2 respi-
ratory challenge, with undetectable replication within 4 d in seven
of eight animals receiving 50 μg of RFN. Cross-neutralization activity
against SARS-CoV-2 variant B.1.351 decreased only approximately
twofold relative to WA1/2020. In addition, neutralizing, effector an-
tibody and cellular responses targeted the heterotypic SARS-CoV-1,
highlighting the broad immunogenicity of RFN-ALFQ for SARS-
CoV−like Sarbecovirus vaccine development.
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The COVID-19 pandemic, precipitated by severe acute re-spiratory syndrome coronavirus 2 (SARS-CoV-2), continues
to threaten global public health and economies. Threats of fu-
ture outbreaks also loom, as evidenced by three emergent SARS-
like diseases caused by zoonotic Betacoronaviruses in the last two
decades. While several emergency use authorized (EUA) vaccines
currently in use are expected to curb both disease and transmission
of SARS-CoV-2 (1–6), the emergence of circulating variants of
concern (VOCs) less sensitive to vaccine-elicited immunity has
raised concerns for sustained vaccine efficacy (7). Logistical chal-
lenges of vaccine production, distribution, storage, and access for
these vaccines must be resolved to achieve resolution to the pan-
demic (8, 9). The rapid and unparalleled spread of SARS-CoV-2
has driven an urgent need to deploy scalable vaccine platforms to
combat the ongoing pandemic and mitigate future outbreaks.
Current vaccines primarily focus the immune response on the
spike glycoprotein (S) as it mediates host cell viral fusion and entry.
The receptor-binding domain (RBD) of S engages the primary host
cell receptor, angiotensin-converting enzyme 2 (ACE2), for both
SARS-CoV-2 and SARS-CoV-1, making RBD a promising do-
main for vaccine-elicited immune focus (10–12). Moreover, many
of the potently neutralizing monoclonal antibodies isolated against
SARS-CoV-2 target the RBD (13, 14). Vaccination of nonhuman
primates (NHPs) with RBD-encoding RNA or DNA protects
against respiratory tract challenge, indicating that immune re-
sponses to the RBD can prevent viral replication (15, 16). RBD
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vaccination also elicits cross-reactive responses to circulating
SARS-CoV-2 VOCs in both animals and humans (17, 18), with
decrements against the B.1.351 variant similar to that seen with S
immunogens (19). The breadth of RBD immunogenicity is further
supported by the ability of RBD-specific monoclonal antibodies
isolated from SARS-CoV-1 convalescent individuals to cross-
neutralize SARS-CoV-2 (20, 21). These findings suggest poten-
tial for RBD-based vaccines being efficacious against SARS-CoV-2
variants and other related coronavirus species.
Approaches to improve immunogenicity of S or RBD protein
vaccines include optimizing antigen presentation and coformu-
lating with adjuvants to enhance the protective immunity. One
common approach to enhance the induction of adaptive immune
responses is the multimeric presentation of antigen, for example, on
the surface of nanoparticles or virus-like particles (22). Presenting
RBD in ordered, multivalent arrays on the surface of self-assembling
protein nanoparticles is immunogenic and efficacious in animals
(23–28), with improved immunogenicity relative to monomeric sol-
uble RBD and cross-reactive responses to variants (17, 24, 26).
However, it is unknown whether RBD nanoparticle vaccines protect
against infection in primates, which have become a standard model
for benchmarking performance of vaccine candidates by virological
and immunologic endpoints. Liposomal adjuvants incorporating QS-
21, such as that used in the efficacious varicella zoster vaccine,
SHINGRIX, may augment protective immunity to SARS-CoV-2
vaccines. Such adjuvants have superior humoral and cellular im-
munogenicity relative to conventional adjuvants (29, 30).
Here, we evaluate the use of a ferritin nanoparticle vaccine
presenting the SARS-CoV-2 RBD (RFN) adjuvanted with the
Army Liposomal Formulation QS-21 (ALFQ) (31). Both ferritin
nanoparticles and ALFQ have been evaluated for vaccination
against multiple pathogens in humans in phase 1 clinical trials
(32–34). We demonstrate, in an NHP model, that immunization
with RFN induces robust and broad antibody and T cell responses,
as well as protection against viral replication and lung pathology
following high-dose respiratory tract challenge with SARS-CoV-2.
Results
Vaccine and Animal Study Design. A SARS-CoV-2 RBD ferritin
nanoparticle vaccine (RFN) was designed as a ferritin-fusion
recombinant protein that self-assembles into a 24-mer nano-
particle displaying a multivalent, ordered array of RBD on its
surface. Briefly, the RBD protein sequence (residues 331 to 527)
derived from the Wuhan-Hu-1 genome sequence (GenBank ac-
cession number MN908947.3) was covalently linked to the
C-terminal region of the Helicobacter pylori ferritin molecule.
Twenty-three rhesus macaques were immunized with either 50 μg
or 5 μg of RFN, or sham-immunized with phosphate-buffered saline
(PBS) (n = 7/8 per group), at study weeks 0 and 4 (Fig. 1A). RFN
was adjuvanted with ALFQ, which contains synthetic mono-
phosphoryl 3-deacyl lipid A and QS-21. Animals were challenged 4
wk after the last immunization via combined intratracheal (IT, 1.0
mL) and intranasal (IN, 0.5 mL per nostril) inoculation of a 106
TCID50 (50% tissue culture infectious dose) dose of SARS-CoV-2
virus (WA1/2020). Animals were followed for 7 d (n = 12) or 14 d
(n = 11) following challenge for immunological, virological, and
pathologic assessments.
Humoral Responses to Vaccination. Multiple vaccine-matched hu-
moral immune responses were measured longitudinally in serum
following vaccination. First, binding antibody responses to the
SARS-CoV-2 prefusion stabilized S protein (S-2P) (35) were
assessed by Meso Scale Discovery (MSD) sandwich electro-
chemiluminescent immunoassay. Immunization with either 5 μg
or 50 μg of RFN elicited S-specific IgG 2 wk following the prime
(21,896 and 79,109 arbitrary units (AU)/mL, respectively) (Fig. 1B).
These responses increased 2 wk following the second immunization
(420,249 and 293,509 AU/mL). Boosting was greater with the 5-μg
dose, achieving a 19-fold increase relative to postprime versus ∼3.7-
fold with 50 μg. Responses continued to marginally increase 4 wk
following the second immunization. Unvaccinated control animals
mounted responses ∼1,000-fold over baseline within 2 wk post-
challenge, and these responses were ∼65-fold lower than those in
vaccinated animals after challenge.
Given the importance of the RBD in mediating viral entry and
the majority of neutralizing antibody responses targeting this
domain, RBD-specific humoral responses were also measured by
MSD immunoassay. RFN induced binding antibodies 4 wk fol-
lowing the second immunization, with no significant difference be-
tween vaccine dose groups (Fig. 1C). Vaccinated animals developed
RBD-specific IgG 4 wk following the prime (506,123 and 553,705
AU/mL in the 5- and 50-μg groups, respectively) comparable in
magnitude to those against the S protein, consistent with an RBD-
focused response. To confirm these findings, the on-rate association
between serum antibodies and RBD antigen was measured by
biolayer interferometry and longitudinal responses exhibited a
similar profile as S-specific binding (SI Appendix, Fig. S1). Again,
vaccine dose groups did not differ. Functional activity of serum
antibodies to inhibit ACE2 binding to the RBD antigen was also
measured and showed comparably high-magnitude responses eli-
cited by RFN at both the 5- and 50-μg doses (Fig. 1D).
Neutralizing antibody responses against SARS-CoV-2 using a
pseudovirus assay followed a pattern similar to the S-specific
binding responses (Fig. 1E). Peak ID50 values (50% inhibitory
dilution—the reciprocal of the serum dilution necessary to
achieve 50% neutralization) of 14,540 and 21,298 were observed
2 wk following the boost for the 5- and 50-μg RFN doses, re-
spectively. Neutralizing responses increased markedly between
the prime and boost, rising 48- and 32-fold between study weeks
2 and 6. Among the 50-μg RFN−vaccinated animals followed 2
wk postchallenge, neutralizing responses declined 6 wk postboost
by ∼1 log relative to peak values, indicating neutralizing re-
sponses may decay more quickly than binding antibodies.
Neutralizing responses were also evaluated using an authentic
intact SARS-CoV-2 virus (WA1/2020 isolate) and a focus re-
duction neutralization assay (36). Robust neutralizing titers were
detected in all RFN-vaccinated animals (Fig. 1F). Median ID50
values were ∼3,800 for both dose groups, though slightly more
variable with 5-μg dosing. This result paralleled responses assessed
by a pseudovirus assay (Fig. 1 E and G). Since serum from con-
valescent COVID-19 human cases is frequently used as a bench-
marking reference for vaccine immunogenicity in clinical and
preclinical studies, we compared RFN-vaccinated macaque pseu-
dovirus neutralizing titers to those of 41 convalescent individuals 4
wk to 8 wk post−COVID-19. Responses in the 50-μg group were,
on average, 13-fold higher than those of convalescent individuals,
whereas titers from the 5-μg group were ∼10-fold higher,
Significance
The emergence of SARS-CoV-2 variants of concern (VOCs) that
reduce the efficacy of current COVID-19 vaccines is a major
threat to pandemic control. We evaluate a SARS-CoV-2 spike
receptor-binding domain ferritin nanoparticle protein vaccine
(RFN) in a nonhuman primate challenge model that addresses
the need for a next-generation vaccine with increased pan-
SARS breadth of coverage. RFN, adjuvanted with a liposomal-
QS21 formulation (ALFQ), elicits humoral and cellular immune
responses with excellent breadth and potency against SARS-
CoV-2 VOCs and SARS-CoV-1, and protects against high-dose
respiratory tract challenge with SARS-CoV-2. Our results
support consideration of RFN for vaccine development against
multiple concerning members of the Sarbecovirus subgenus of
Betacoronaviruses.
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indicating that RFN-elicited neutralizing antibody activity exceeds
that observed in the first months following human infection. Thus,
RFN vaccination generated strong RBD-specific binding anti-
bodies with potent neutralizing activity that blocks the interaction
between the RBD and the host ACE2 receptor.
Nonneutralizing antibody effector functions may be associated
with vaccine-mediated protection against viruses including
SARS-CoV-2 (37–39). Strong IgG-mediated cellular opsonization
responses were observed following the second immunization, whereas
IgM and IgA responses were more modest (SI Appendix, Fig.
S2A–C). Serum antibody-dependent phagocytosis mediated by either
monocytes (antibody-dependent cellular phagocytosis [ADCP]) or
neutrophils (antibody-dependent neutrophil phagocytosis [ADNP])
as well as complement deposition (antibody-dependent complement
deposition [ADCD]) responses were also robust in both vaccinated
groups and consistently peaked at week 6 (SI Appendix, Fig. S2D–F).
A similar pattern was seen for antibody-dependent trogocytosis (40)
(SI Appendix, Fig. S2G). Overall, 5 μg of RFN achieved equal Fc-
mediated effector functions compared to 50 μg, although ADCD
responses trended ∼1.25-fold greater with the higher dose.
Virus-Specific T Cell Responses. SARS-CoV-2−specific T cell im-
munity is associated with reduced disease severity and can in-
fluence antibody responses (41, 42). We assessed S-specific T cells
in peripheral blood mononuclear cells (PBMCs) by in vitro pep-
tide stimulation and intracellular cytokine staining using a 19-color
multiparameter flow cytometry panel for detailed functional
characterization of T cell responses from RFN vaccination. A
vigorous, dose-dependent Th1 (TNF, IL-2, IFN-γ) CD4+ T cell
response was observed in all RFN-vaccinated animals 4 wk after
the second vaccination, ranging from 0.4 to 5.2% of memory cells
(Fig. 2A). These S-specific Th1 cells were polyfunctional in qual-
ity, a property associated with control of other pathogens (43), as a
large proportion concurrently expressed multiple Th1 cytokines
(SI Appendix, Fig. S3A). Th2 responses were low or undetectable
(Fig. 2B), with median Th1/Th2 ratios of ∼20 among 50-
μg−vaccinated animals with evidence of a Th2 response (SI Ap-
pendix, Fig. S3B). Modest CD8+ T cell responses were observed
in about half of the animals and were more prominent in recipi-
ents of 50 μg than 5 μg of RFN (SI Appendix, Fig. S3C). Response
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Fig. 1. RFN vaccine−elicited binding and neutralizing antibody responses to SARS-CoV-2. Humoral immune responses were measured in vaccinated ma-
caques. (A) Rhesus macaque vaccination, challenge, and sampling schedule. Animals were immunized with either 50 μg or 5 μg of RFN-ALFQ at weeks 0 and 4;
control animals received PBS (N = 7 or 8 per group); 1 × 106 TCID50 of SARS-CoV-2 was administered 4 wk after the last vaccination. (B) Serum
SARS-CoV-2 S-specific IgG responses assessed by MSD immunoassay every 2 wk following vaccination. Data are depicted as arbitrary units per milliliter of IgG
binding. Thick lines indicate geometric means within each group, and thin lines represent individual animals. Serum SARS-CoV-2 RBD-specific IgG (C) and
inhibition of ACE2 binding to the RBD (D) 4 wk after last vaccination were measured by MSD immunoassay. (E) Serum SARS-CoV-2 S-specific pseudovirus
neutralization every 2 wk following vaccination. Virus neutralization reciprocal ID50 is shown. Thick lines indicate geometric means within each group, and
thin lines represent individual animals. (F) Authentic SARS-CoV-2 WA1/2020 virus neutralization at 4 wk after last vaccination. (G) Pseudovirus neutralization
activity 4 wk postboost was compared to a panel of human convalescent sera (n = 41 samples). Bars indicate the geometric mean titer. Symbols represent
individual animals and overlap with one another for equal values where constrained. In B and E, gray arrows indicate the time of immunization; maroon Xs
indicate time of challenge. Significance was assessed using a Kruskal−Wallis test followed by a Dunn’s posttest.
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Additional CD4+ T cell functions important for the devel-
opment of antibody responses were evaluated. S-specific CD4+
T cell IL-21 responses, a surrogate marker of peripheral T fol-
licular helper cell activity, were observed in the majority of an-
imals vaccinated with 50 μg of RFN and in half of the animals
vaccinated with 5 μg of RFN (Fig. 2C). The average frequency in
responders was 0.15%. The CD4+ T cell activation marker,
CD40L, which promotes B cell antibody isotype switching, was
highly expressed by S-specific cells (Fig. 2D). Responses ranged
from ∼1 to 7% after 50 μg of RFN and were observed in all eight
animals, whereas response rates and magnitude were slightly
reduced with the 5-μg dose (∼0.7 to 2% in six of seven animals).
Overall, these data show that adjuvanted RFN induced robust
Th1-polarized polyfunctional CD4+ T cells favorable for viral
clearance and with critical B cell help capability.
SARS-CoV-2 Challenge Efficacy and Immune Correlates of Protection.
To assess the protective efficacy of RFN vaccination, animals
were challenged with high-dose (106 TCID50) SARS-CoV-2
WA1/2020 administered via the simultaneous IN/IT routes 4 wk
following the second immunization. The presence of viral RNA
was assessed in both the upper (nasopharyngeal [NP] swabs and
saliva) and lower (bronchoalveolar lavage fluid [BAL]) respira-
tory tract. Measurements were made of both total RNA and
subgenomic E messenger RNA (sgmRNA), the latter considered
a more specific indicator of viral replication (44, 45). Unvacci-
nated control animals all showed evidence of a robust infection,
with mean levels of sgmRNA in the BAL of ∼106 copies per mL,
and, in the NP swabs, of ∼107 copies per mL at day 2 postchallenge
(Fig. 3). Moreover, viral replication was sustained at >104 copies
sgmRNA per mL for 7 d in the upper airways. In RFN-vaccinated
animals, the magnitude and duration of viral replication was
markedly reduced. In the 50-μg group, day 1 sgmRNA was reduced
by 1 and 2 logs in the BAL and NP swabs, respectively. Rapid
clearance was observed by day 2 in five of eight animals in the upper
airways and four of eight in the lower airways. Both airways were
void of replicating virus in all but one animal by day 4. Viral control
was also apparent after 5-μg RFN vaccination. Reductions in BAL
and NP swab sgmRNA on day 1 were similar to that achieved with
50 μg, while more breakthrough replication was apparent 2 d after
challenge. Clearance was observed by day 4 in five of seven animals
in the upper airways and six of seven in the lower airways. Repli-
cating virus was absent in the airways in all but two animals by day 7.
Viral replication was detected in saliva in all control animals
on day 1 and persisted in five animals through day 4 (Fig. 3C).
Values were lower than those in BAL or NP swabs and tapered to
undetectable levels more rapidly. Fewer vaccinated animals con-
tained sgmRNA in their saliva, and replicating virus was detected
in only one animal from each vaccine dose group starting on day 2.
The kinetics of SARS-CoV-2 total RNA, which is more likely to
reflect material from the viral inoculum, paralleled results de-
scribed above for sgmRNA in BAL, NP swabs, and saliva (SI
Appendix, Fig. S4).
Development of adaptive immune responses against SARS-CoV-2
following challenge can also provide evidence of viral replication in
infected animals. Antibodies to the viral nucleocapsid (N) protein,
which is not present in the vaccine, were measured at study weeks 9
and 10 using the MSD immunoassay. Unvaccinated control animals
developed N-specific binding IgG responses within 2 wk following
challenge, while responses were not observed in RFN-vaccinated
animals (SI Appendix, Fig. S5). This suggests absence of a de novo
response to the challenge virus in the vaccine groups and is consistent
with limited viral replication.
To identify vaccine-elicited immune responses that contribute
to control of viral replication following challenge, we performed
an exploratory immune correlates analysis. SARS-CoV-2−specific
humoral and cellular immune responses among RFN-vaccinated
animals were assessed for inverse associations with viral replica-
tion in the upper respiratory tract, as represented by viral
sgmRNA in NP swabs 2 d postchallenge, when the greatest vari-
ation in viral burden was observed. Several humoral responses at
the time of challenge were inversely associated with viral clear-
ance: IgG opsonization (rho = −0.63, P = 0.015), IgA opsoniza-
tion (rho = −0.53, P = 0.046), and ADCD (rho = −0.56, P = 0.032;
Spearman correlation; two-tailed test). Trends were also observed
for serum inhibition of ACE2 binding to S (rho = −0.52, P = 0.05)
and the RBD (rho = −0.46, P = 0.088), as well as pseudovirus
neutralization titers (rho = −0.46, P = 0.089) (SI Appendix, Fig.
S6 A–F). Neither S-specific CD4+ or CD8+ T cell responses (SI
Appendix, Fig. S6 G–I) nor authentic intact virus neutralization
were associated with rapid clearance. These data indicate that
serum humoral responses, including those with effector functions,
may serve as a useful immune correlate of protection.
Respiratory Tract Pathology and Antigen Expression. Vaccine effi-
cacy was also assessed by histopathological analysis of lung tissue
from three to five macaques from each group necropsied at day 7
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Fig. 2. RFN vaccine−elicited SARS-CoV-2 S-specific CD4+ T cell responses. T cell responses were assessed by SARS-CoV-2 S peptide pool stimulation and in-
tracellular cytokine staining of PBMCs collected 4 wk after last vaccination. S-specific memory CD4+ T cells expressing the indicated markers are shown as
follows: (A) Th1 cytokines (IFNγ, TNF, and IL-2), (B) Th2 cytokines (IL-4 and IL-13), (C) IL-21, and (D) CD40L. Boolean combinations of cytokine-positive memory
CD4+ T cells were summed in A and B. Probable positive responses, defined as >3 times the group background at baseline, are depicted as closed symbols.
Positivity rates within each group are shown below each graph as a fraction. Box plot horizontal lines indicate the mean; top and bottom reflect the minimum
and maximum. Significance was assessed using a Kruskal−Wallis test followed by a Dunn’s posttest.
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postchallenge. By this point, all unvaccinated animals had de-
veloped evidence of multifocal, mild to moderate interstitial
pneumonia (Fig. 4A). The pneumonia was characterized by type
II pneumocyte hyperplasia, alveolar edema, alveolar inflamma-
tory and necrotic debris, thickening of alveolar septae, increased
numbers of pulmonary macrophages (including multinucleated
giant cells), and vasculitis of small- to medium-caliber blood
vessels. The middle and caudal lung lobes were most severely
affected in all four unvaccinated animals. Histological evidence
of interstitial pneumonia was not observed in animals from any
of the vaccinated groups (Fig. 4 B and C). However, in each of
the vaccine groups, there was minimal to mild mononuclear to
mixed cellular infiltrates centered on small- to medium-caliber
blood vessels. Immunohistochemistry (IHC) demonstrated
SARS-CoV-2 viral antigen in small numbers of alveolar pneu-
mocytes and macrophages in at least one lung section of every
unvaccinated animal (Fig. 4D). No viral antigen was detected in
the lungs of any of the animals in any of the vaccine groups
(Fig. 4 E and F). Overall, pathological findings were significantly
reduced by vaccination (Fig. 4G). No significant histopathologic
differences were observed between vaccinated and unvaccinated
animals at day 14, consistent with transient SARS-CoV-2 pa-
thology in this model. Mild perivascular infiltrates occasionally
remained in some animals from all groups. In summary, vacci-
nation with 5 μg or 50 μg of RFN prevented moderate disease
and viral protein expression in the lungs.
Cross-Reactive Immunity to Emergent SARS-CoV-2 Variants and
SARS-CoV-1. Given concerns about increased resistance of circu-
lating SARS-CoV-2 viral variants to currently available vaccines,
we assessed serum from RFN-vaccinated macaques for neutral-
izing antibody responses against two VOCs, B.1.1.7 and B.1.351.
In an authentic virus neutralization assay (46), reciprocal neu-
tralization ID50 geometric mean titer (GMT) against B.1.1.7
were 73,983 2 wk following the second 50-μg dose (Fig. 5A). This
translated to ∼3.8-fold greater titers than those against the wild-
type, vaccine-matched WA1/2020 strain. Activity against the two
strains was similar when measured by the pseudovirus neutrali-
zation assay (Fig. 5B). B.1.1.7 cross-reactive responses were ob-
served regardless of vaccine dose, although titers trended lower
with 5 μg of RFN. Neutralizing GMTs against B.1.351 decreased
approximately twofold to 8,070 and 9,876 in the 50-μg-dose group
in the authentic virus and pseudovirus assays, respectively, indi-
cating only a minor diminution in potency compared to WA1/2020
(Fig. 5 A–C). In the same authentic virus assay, average neutral-
ization GMT of human convalescent plasma was 465, an ap-
proximately fivefold reduction in titer compared to the WA1/2020
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Fig. 3. Viral replication in the lower and upper airways after RFN vaccina-
tion and subsequent SARS-CoV-2 respiratory challenge. The sgmRNA for the
E (Envelope) target (copies per milliliter) were measured following challenge
in (A) BAL, (B) NP swabs, and (C) saliva of vaccinated and control animals for
1 wk (n = 7 or 8 per group) or 2 wk (n = 3 or 4 per group) following IN and IT
SARS-CoV-2 (WA1/2020) challenge of vaccinated and control animals. Spec-
imens were collected 1, 2, 4, 7, 10, and 14 d postchallenge. Dotted lines
demarcate assay lower limit of linear performance range (log 10 of 2.65
corresponding to 450 copies per mL); positive values below this limit are
plotted as 450 copies per mL. Open symbols represent animals with viral
loads below the limit of detection of the assay. Box plot horizontal lines
indicate the mean; top and bottom reflect the minimum and maximum.
Significant differences between control and vaccinated animals at day 2
postchallenge are indicated. Significance was assessed using a Kruskal−
Wallis test followed by a Dunn’s posttest.

















Fig. 4. Histopathology and virus detection in the lungs following
SARS-CoV-2 challenge. Lung parenchymal tissue was assessed for pathology
and viral antigen 7 d postchallenge. (A–C) Paraffin-embedded sections were
stained with hematoxylin and eosin and shown for animals that received PBS
(A), 50 μg of RFN (B) and 5 μg of RFN (C). Inflammatory debris (white star),
type II pneumocyte hyperplasia (black arrow), edema (black triangle), and
vasculitis of small- to medium-caliber blood vessels (white arrows) is indi-
cated. (Scale bars, 50 μm.) (D–F) SARS-CoV-2 nucleocapsid detected by IHC in
alveolar pneumocytes, pulmonary macrophages, and endothelial cells ap-
pears as brown aggregates. (Scale bars, 100 μm.) Representative images are
shown. (G) Each pathologic finding was quantified for six lung sections and
reported as a combined TIIPH score for all animals necropsied 7 d
postchallenge.
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strain (19). Thus, RFN vaccination elicited broadly reactive neu-
tralizing antibody responses with potent activity against two im-
portant variants, exceeding that of convalescent individuals. Serum
binding to the variant forms of SARS-CoV-2 was also assessed by
biolayer interferometry (SI Appendix, Fig. S7). In both vaccine
groups, no changes in binding to B.1.1.7 were observed, while
responses to B.1.351 trended ∼15% lower.
In addition to SARS-CoV-2 VOCs, another open question in
the field is the ability of existing SARS-CoV-2 vaccine platforms
to protect against future SARS-CoV−like coronavirus outbreaks.
Cross-protective vaccine-elicited immunity against SARS-CoV-1
may be a useful metric to address this question. We measured IgG
antibody responses able to bind SARS-CoV-1 RBD by biolayer
interferometry in macaque serum at week 2 following the second
vaccination. All RFN-vaccinated animals developed cross-reactive
binding antibodies to SARS-CoV-1 at levels approximately half
those to SARS-CoV-2 (Fig. 5D and SI Appendix, Fig. S1). Binding
responses were also measured to a series of SARS-CoV-1 and
SARS-CoV-2 antigens, using a Luminex assay (SI Appendix, Fig.
S8). Strong binding responses were observed to the SARS-1 S1
subunit and RBD, but not against the S2 subunit or N-terminal
domain. SARS-CoV-1 RBD-specific binding antibody responses
were ∼70% that of the SARS-CoV-2 response. The functional
capacity of these cross-binding antibodies to mediate effector ac-
tivity was assessed in an ADCP assay using SARS-CoV-1 trimeric

























































































































































































































C Immunization Neutralization 
assay
ID50 GMT ID50 GMT fold-
change from WA1
WA1   B.1.1.7  B.1.351   B.1.1.7 B.1.351
50 μg Authentic virus 19643 73983 8070 3.8 -2.4
5 μg Authentic virus 8299 34637 4049 4.2 -2.0
50 μg Pseudovirus 21299 19070 9876 -1.1 -2.2




Fig. 5. Cross-reactive immune responses to SARS-CoV-2 variants and SARS-CoV-1. Serum and PBMC collected 2 wk after the last vaccination was assessed for
cross-reactivity to VOCs and SARS-CoV-1. (A) Authentic virus and (B) pseudovirus neutralizing antibody responses to variants B.1.1.7 and B.1.351. Corre-
sponding responses to SARS-CoV-2 WA1/2020 authentic virus and Wuhan-1 pseudovirus are shown. Bars indicate the GMT. (C) Reciprocal ID50 GMT fold
change from wild-type neutralization (WA1 or Wuhan-1) with statistical significance indicated (P < 0.05, *; P < 0.01, **). (D) Serum binding responses to
SARS-CoV-1 RBD assessed by biolayer interferometry. (E) Antibody-dependent cellular phagocytosis of SARS-CoV-1 S trimer-coated fluorescent beads. (F)
Authentic SARS-CoV-1 (Urbani) neutralization titers (ID50). (G) SARS-CoV-1 (Urbani) pseudovirus neutralization (ID90). (H) SARS-CoV-1 (Urbani) S-specific
memory CD4+ Th1 and (I) CD8+ responses assessed by peptide pool stimulation and ICS (INFγ, IL-2, and TNF). Significance was assessed with a Kruskal−
Wallis test followed by a Dunn’s posttest. Bars indicate the GMT.
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plasma of all vaccinated animals and were comparable between
the dose groups (Fig. 5E).
Neutralizing titers against SARS-CoV-1 were measured using
both authentic virus and pseudovirus neutralization assays, with
cross-neutralizing responses observed in most RFN-vaccinated
animals (Fig. 5 F and G). Substantive (GMT of 160) authentic
virus neutralization titers were elicited by 50 μg of RFN 2 wk
following the second immunization. SARS-CoV-1 pseudovirus
neutralization activity was also observed in both the 50- and 5-μg
groups, although background in a subset of control animals
limited interpretation of both assays.
To assess T cell cross-reactivity to SARS-CoV-1, we evaluated
whether the RFN vaccine−elicited T cells could recognize
SARS-CoV-1 S. PBMCs stimulated with SARS-CoV-1 S peptide
pools were stained for intracellular cytokine expression to
quantitate cross-reactive T cells. Significant CD4+ T cell Th1
responses were observed following the 50-μg RFN vaccination series,
though they were approximately fivefold lower in magnitude than
those to SARS-CoV-2 S (Fig. 5H). SARS-CoV-1 S-specific CD40L
responses were comparable to the Th1 responses for both dose
groups (SI Appendix, Fig. S9A). IL-21 and Th2 CD4+ T cell re-
sponses were minimal or negligible (SI Appendix, Fig. S9 B and C).
Cross-reactive CD8+ T cells were elicited and similar in magnitude
to SARS-CoV-2-specific responses (∼0.1 to 0.3%) (Fig. 5I), sug-
gesting that the CD8+ T cell RBD epitope specificities elicited by
RFN vaccination may be conserved. Again, responses trended
greater with the higher vaccine dose. These data indicate that
S-specific CD4+ and CD8+ T cells generated by ALFQ-adjuvanted
RFN were able to cross-react with sequence divergent SARS-CoV-1.
Discussion
New SARS-CoV-2 vaccines may be needed to address concerns
regarding emerging virus variants less sensitive to immunity eli-
cited by current vaccines (1, 47–50). In this study, we evaluated a
candidate RFN vaccine adjuvanted with ALFQ in rhesus ma-
caques and observed robust and broad humoral and T cell re-
sponses and protection from high-dose respiratory tract challenge.
Binding, neutralizing, and effector antibody responses were elicited
in all animals and were of exceptional magnitude, with reciprocal
peak mean neutralizing antibody titers exceeding 104. S-specific
CD4+ T cell responses surpassed 0.5% of memory cells and were
predominantly of the Th1 phenotype. Using a rigorous challenge
model in which peak viral loads of control animals achieved 106 and
106.5 median sgmRNA copies in the upper and lower airways, re-
spectively, and sgmRNA persisted for 7 d, replicating virus was
rapidly cleared in the airways of vaccinated animals. Absence of
N-specific humoral responses following challenge in vaccinated
animals further suggested little to no viral replication. Cross-reactive
antibody responses were either higher or similar against the B.1.1.7
VOC in authentic and pseudovirus neutralization assays, while
B.1.351 reactivity was diminished only approximately twofold. Ad-
ditionally, binding and functional antibodies were also reactive to
SARS-CoV-1, which is 36% amino acid sequence divergent from
SARS-CoV-2 in the RBD (51). Overall, these data indicate broad,
potent, and efficacious immunity elicited by RFN-ALFQ.
This study provides strong evidence that RBD-directed vac-
cination in primates is able to protect against SARS-CoV-2 in-
fection and elicit neutralization breadth against variant B.1.351,
which has shown the greatest resistance to neutralization by
vaccinee sera (19, 52, 53). While many RBD-based immunogens
have been shown to be immunogenic in small and large animal
models (24–27), limited studies assessed efficacy against viral
challenge and neutralization activity against VOCs. A recent
macaque study investigated the immunogenicity and protective
efficacy of a three-dose regimen of an RBD-ferritin nanoparticle-
based vaccine (RBD scNP) and reported efficacy upon challenge,
with no sgmRNA detected in the upper or lower airways of vac-
cinated animals at day 2 postchallenge (54). Neutralizing antibody
titers against the B.1.1.7 variant were equivalent to WA1/2020,
while B.1.351 reactivity was decreased threefold. Here, RFN
vaccination also elicited B.1.1.7 neutralization similar to RBD
scNP, and neutralized B.1.351 with twofold reduction in potency
relative to WA1/2020. In another study, vaccination with RBD
fused to the Fc domain of human IgG1 reduced total viral RNA
following challenge in cynomolgus macaques, although virus rep-
lication was not assessed (55). On a technical note, two authentic
virus neutralization assays were used in this study to measure se-
rum activity against WA1/2020 at either 4 wk or 2 wk following the
second vaccination, with VOCs included in the latter. Our intent
was to compare results within rather than between assays. How-
ever, despite these differences, WA1/2020 ID50 values were within
fivefold of one another, demonstrating consistent results in or-
thogonal assays. Our findings demonstrate RBD-specific immu-
nity elicited by a two-dose vaccine regimen is protective and,
importantly, cross-neutralizes the more resistant B.1.351 variant.
The immunogenicity and efficacy of ALFQ-adjuvanted RFN
compares favorably to preclinical macaque data reported for
three COVID-19 vaccines authorized for emergency use. RFN
vaccination elicited peak mean SARS-CoV-2 pseudovirus neu-
tralization reciprocal titers of 14,540 and 21,298 for the 5- and
50-μg groups, respectively, using an assay harmonized in a large
concordance survey. Reported titers for EUA vaccines ranged
from 408 to 1,862 (56–58), although results from the assays may
not be directly comparable to those reported here, due to vari-
ability across laboratories. While neutralizing activity is unlikely
to be the sole determinant of vaccine-mediated protection, it has
been predictive of efficacy in human trials (1). Therefore, the
neutralizing titers elicited by RFN relative to those elicited in
NHP studies by efficacious vaccines currently in clinical use
strongly suggest that RFN would be protective in humans. In
addition, breadth against the B.1.351 VOC appears remarkable,
as the modest approximately twofold reduction in B.1.351 neu-
tralization activity relative to wild-type virus reported here is less
than the ∼10- to 12-fold reduction in mRNA vaccinee sera as
assessed by the same authentic virus neutralization assay and the
same laboratory (19). The most advanced platform closest in de-
sign and composition to RFN is NVX-CoV2373, a prefusion spike
nanoparticle vaccine delivered with a saponin-based Matrix-M
adjuvant. NVX-CoV2373 elicited neutralizing antibody titers of
6,400 to 17,000 in macaques (59, 60). T cell immunity was also
pronounced with RFN, as S-specific Th1 CD4+ T cells ranged
from 0.5 to 5% following 50 μg of RFN. Reported peak values in
NHPs vaccinated with EUA vaccines were 0.1 to 0.2% (56–58).
Among the RFN-elicited humoral immune response measure-
ments associated with rapid viral clearance, some novel correlates
were identified, including antibodies that bind cell surface S pro-
tein, and ACE2-inhibiting antibodies, as well as ADCD, which has
been reported in a previous study (16). A trend was also observed
for pseudovirus neutralization, a correlate identified in several
other preclinical vaccine studies (16, 58, 61–63), as well as in
studies of vaccinated individuals and individuals with prior
SARS-CoV-2 infection (64, 65).
The comparison of low- or high-dose vaccine regimens pre-
sented here demonstrates that immune responses did not sig-
nificantly differ between the 5- and 50-μg doses, although the 50-
μg group trended toward higher responses and a slightly earlier
resolution of viral load. The power to detect these differences
may have been limited by small sample sizes. It is likely that, as
doses decrease, protective efficacy will wane, and such experi-
ments may allow further elucidation of correlates of protection.
This absence of a strong dose titration effect suggests that vac-
cination with the lower dose may be possible for dose-sparing
purposes, although clinical testing and assessment of response
durability are required. The mechanism(s) underlying the robust
humoral and T cell immune responses elicited by RFN-ALFQ
vaccination warrants further investigation and likely includes a
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combination of the ALFQ adjuvant and the highly ordered anti-
gen array displayed on the ferritin nanoparticle, both of which
stimulate adaptive immunity (22, 66). Adjuvanting ferritin nano-
particle vaccines with ALFQ increased immunogenicity relative to
aluminum hydroxide in mice (66, 67), and ongoing studies in
macaques aim to assess the contribution of the adjuvant to vaccine
immunogenicity and efficacy in primates.
In addition to the RFN vaccine described here, we have also
developed a similar ferritin nanoparticle immunogen displaying
the full prefusion stabilized SARS-CoV-2 spike glycoprotein
(SpFN) and reported its immunogenicity and efficacy in NHPs
(68). Compared to two-dose SpFN regimens, RFN elicited binding
and neutralizing antibody and T cell responses of a similar mag-
nitude, albeit with a trend toward slightly lower titers. Post-
challenge control of viral replication was also similar, although viral
clearance after SpFN vaccination trended faster from the BAL
at day 2 postchallenge and from NP swabs by day 4. The overall
magnitude of these differences was small and suggests that both the
RBD and S proteins are similarly immunogenic and protective
when complexed to ferritin nanoparticles and administered with
ALFQ adjuvant at these vaccine doses. A potential benefit of RBD
vaccination is avoiding “antigenic sin” against nonneutralizing
epitopes in the S2 subunit among antigen-experienced individuals.
However, S-based immunogens may offer the advantage of
broadening the specificity of the immune response to other do-
mains and subdomains of the spike protein, limiting potential for
viral escape. These findings support further clinical development of
both products.
There exists a strong potential for future pandemics arising
from zoonotic SARS-CoV−like Betacoronaviruses entering into
humans. We report SARS-CoV-2 RFN vaccine−elicited re-
sponses that cross-react with the S glycoprotein of SARS-CoV-1,
including binding antibody titers within an order of magnitude of
those to SARS-CoV-2. The observed cross-neutralizing and
binding reactivity to SARS-CoV-1 suggests that adjuvanted RFN
may be a viable candidate for vaccination against future Sarbe-
covirus outbreaks. Work is ongoing to elucidate the potential
mechanisms of cross-protective responses in this study, including
epitope mapping of the antibody binding responses. Taken to-
gether, these findings support continued development of RFN
vaccines for managing COVID-19 and related SARS-CoV−like
virus outbreaks.
Materials and Methods
Vaccine and Adjuvant Production.
DNA plasmid construction and preparation. The SARS-CoV-2 RBD-ferritin con-
struct was derived from the Wuhan-Hu-1 strain genome sequence (GenBank
accession number MN9089473) comprising residues 331 to 527. RBD was
attached to H. pylori ferritin using a GSGGGG linker followed by a short
sequence (ESQVRQQFSK) derived from bullfrog ferritin (69) and synthesized
by GenScript, to include an N-terminal hexa-histadine (his) tag for purifica-
tion. Additional point mutations (Y453R, L518N, L519K, H520S) were intro-
duced in the RBD, using a modified QuikChange site-directed mutagenesis
protocol (Agilent Technologies) and designated as construct RFN_131. The
construct used a prolactin leader sequence (70). Plasmid DNA generated by
site-directed mutagenesis was prepared from Eschericia coli Stbl3 cells.
Large-scale DNA isolation was performed using either endo free Maxiprep,
Megaprep, or Gigaprep kits (Qiagen).
Immunogen expression and purification. SARS-CoV-2 RFN_131 immunogen (RFN)
was expressed in Expi293 mammalian cell lines by transient transfection
using Turbo293 transfection reagent (Speed Biosystems). Expression cultures
were grown in polycarbonate baffled shaker flasks at 34 °C and 8% CO2 at
120 rpm. Cells were harvested 5 d posttransfection via centrifugation at
3,500 × g for 30 min. Culture supernatants were filtered with a 0.22-μm filter
and stored at 4 °C prior to purification. RFN was purified using Ni-NTA af-
finity chromatography. One milliliter of Ni-NTA resin (Thermo Scientific) was
used to purify protein from 1 L of expression supernatant. Ni-NTA resin was
equilibrated with five column volumes (CV) of PBS (pH 7.4) followed by su-
pernatant loading at room temperature (RT). Unbound protein was re-
moved by washing with 200 CV of PBS, followed by 50 CV of 10 mM
imidazole in PBS. Bound protein was eluted with 220 mM imidazole in PBS.
Purification purity was assessed by sodium dodecyl sulfate polyacrylamide
gel electrophoresis; RFN was concentrated in the presence of 5% glycerol
and then further purified by size-exclusion chromatography using a 16/
60 Superdex-200 purification column. Endotoxin levels for ferritin nano-
particle immunogens were evaluated (Endosafe nexgen-PTS, Charles River
Laboratories), and 5% vol/vol glycerol was added prior to filter sterilization
with a 0.22-μm filter, flash freezing in liquid nitrogen, and storage at −80 °C.
Ferritin nanoparticle formation was confirmed by negative-stain electron
microscopy and dynamic light scattering by determining the hydrodynamic
diameter at 25 °C using a Malvern Zetasizer Nano S (Malvern Panalytical)
equipped with a 633-nm laser.
Adjuvant preparation. ALFQ formulation was prepared as previously described
(71, 72). ALFQ is a unilamellar liposome comprising dimyristoyl phosphati-
dylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), cholesterol
(Chol), and synthetic monophosphoryl lipid A (3D-PHAD) (Avanti Polar Lipids)
and QS-21 (Desert King). DMPC and cholesterol were dissolved in chloroform,
and DMPG and 3D-PHAD were dissolved in chloroform:methanol 9:1. Lipids
were mixed in a molar ratio of 9:1:12.2:0.114 (DMPC:DMPG:Chol:3D-PHAD),
and the solvent was removed by rotary evaporation. Lipids were suspended in
Sorenson’s PBS, pH 6.2, microfluidized to form small unilamellar vesicles and
filtered. QS-21 was solubilized in Sorenson’s PBS, pH 6.2, filtered and added to
the vesicles to form ALFQ. The final lipid ratio was 9:1:12.2:0.114:0.044
(DMPC:DMPG:Chol:3D-PHAD:QS-21).
Immunogen formulation. RFN was diluted in Dulbecco’s PBS to 0.1 mg/mL or
0.01 mg/mL and mixed 1:1 with 2× ALFQ on a tilted slow-speed roller at RT for
10 min, followed by incubation at 4 °C for 50 min. Reagents were equilibrated
to RT before use, and immunizations were performed within 4 h of vaccine
formulation. Each vaccine comprised a 1.0-mL solution of RFN formulated with
ALFQ. The 3D-PHAD and QS-21 doses were 200 and 100 μg, respectively.
Study Design and Procedures. Twenty-three male and female specific path-
ogen−free, research-naïve Chinese-origin rhesus macaques (age 3 y to 7 y)
were distributed—on the basis of age, weight, and sex—into three cohorts
of seven or eight animals (SI Appendix, Table S1). Animals were vaccinated
intramuscularly with either 50 μg or 5 μg of RFN, formulated with ALFQ, and
control group animals received 1 mL of PBS, in the anterior proximal quadri-
ceps muscle, on alternating sides with each dose in the series. Immunizations
were administered twice, 4 wk apart. Animals were challenged 4 wk after the
second immunization with virus stock obtained through BEI Resources, Na-
tional Institute of Allergy and Infectious Diseases (NIAID), NIH: SARS-Related
Coronavirus 2, Isolate USA-WA1/2020, NR-53780 (Lot# 70038893). Virus was
stored at −80 °C prior to use, thawed by hand, and placed immediately on wet
ice. Stock was diluted to 5 × 105 TCID50/mL in PBS and vortexed gently for 5 s
prior to inoculation via combined IT and IN routes (1 mL each).
All procedures were carried out in accordance with institutional, local,
state, and national guidelines and laws governing animal research included in
the AnimalWelfare Act. Animal protocols and procedures were reviewed and
approved by the Animal Care and Use Committee of both the US ArmyMedical
Research and Development Command (USAMRDC, protocol 11355007.03)
Animal Care and Use Review Office and the Institutional Animal Care and Use
Committee of Bioqual, Inc. (protocol number 20-092),where NHPswere housed
for the duration of the study. USAMRDC and Bioqual, Inc. are both accredited
by the Association for Assessment and Accreditation of Laboratory Animal
Care and are in compliance with the Animal Welfare Act and Public Health
Service Policy on Humane Care and Use of Laboratory Animals. Research was
conducted in compliance with the Animal Welfare Act and other federal
statutes and regulations relating to animals and experiments involving animals
and adheres to principles stated in Guide for the Care and Use of Laboratory
Animals (73).
Convalescent Plasma Samples. A panel of 41 human convalescent-phase
plasma samples was obtained from BEI Resources Repository (n = 30), Ste-
mExpress (n = 7), and a Walter Reed Army Institute of Research institutional
review board-approved leukapheresis protocol (#1386H) (n = 4) for which writ-
ten informed consent was provided by participants. Samples were collected from
males (n = 20) and females (n = 21) ranging in age from 31 y to 71 y. Individuals
donated plasma specimens approximately 4 to 8 wk after laboratory-confirmed
SARS-CoV-2 infection and had histories of asymptomatic-to-mild-to-moderate
clinical presentation. All samples were deidentified prior to use.
Antibody Responses.
Binding antibodies. SARS-CoV-2−specific binding IgG antibodies and ACE2-
inhibiting antibodies were measured using MULTI-SPOT 96-well plates
(MSD). Multiplex wells were coated with SARS-CoV-2 antigens, S and RBD, at
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a concentration of 200 to 400 ng/mL and bovine serum albumin (BSA), which
served as a negative control. Four-plex MULTISPOT plates were blocked with
MSD Blocker A buffer for 1 h at RT while shaking at 700 rpm. Plates were
washed with buffer before the addition of reference standard and calibrator
controls. Serum samples were diluted at 1:1,000 to 1:100,000 in diluent
buffer, then added to each of the four wells. Plates were incubated for 2 h at
RT while shaking at 700 rpm, and then washed. MSD SULFO-TAG anti-IgG
antibody was added to each well. Plates were incubated for 1 h at RT with
shaking at 700 rpm and washed, and then MSD GOLD Read buffer B was
added to each well. Plates were read by the MESO SECTOR SQ 120 Reader.
IgG concentration was calculated using DISCOVERY WORKBENCH MSD
Software and reported as arbitrary units per milliliter.
For binding antibodies that block S or RBD binding to ACE2, antigen-
coated plates were blocked and washed as described above. Assay calibra-
tor and samples were diluted at 1:25 to 1:1,000 in MSD Diluent buffer, then
added to the wells. Plates were incubated for 1 h at RT while shaking at 700
rpm. ACE2 protein conjugated with MSD SULFO-TAG was added, and plates
were incubated for 1 h at RT while shaking at 700 rpm and washed and read
as described above.
Binding antibody measurements by Octet biolayer interferometry were
made using HIS1K biosensors hydrated in PBS prior to use, using an Octet
FortéBio Red96 instrument (Sartorius). All assay steps were performed at
30 °C with agitation set at 1,000 rpm. Baseline equilibration of the HIS1K
biosensors (Sartorius) was carried out with PBS for 15 s, prior to SARS-CoV2
RBD molecules (30 μg/mL diluted in PBS) loading for 120 s. Biosensors were
dipped in assay buffer (15 s in PBS), and dipped in the serum samples (100-
fold dilution) for 180 s, and binding response (nm) was recorded for 180 s.
Virus neutralization.
SARS-CoV-2 and SARS-CoV-1 pseudovirus neutralization. The S expression
plasmid sequences for SARS-CoV-2 and SARS-CoV-1 were codon optimized
and modified to remove the last 18 or 28, respectively, amino acids of the
cytoplasmic tail to improve S incorporation into pseudovirions (PSV). PSV
were produced by cotransfection of HEK293T/17 cells with either a
SARS-CoV-2 S plasmid, derived from the Wuhan-Hu-1 genome sequence
(GenBank accession number MN908947.3), or a SARS-CoV-1 (Sino 1-11,
GenBank accession number AY485277) S plasmid and an HIV-1 pNL4-3 lu-
ciferase reporter plasmid (pNL4-3.Luc.R-E-, NIH HIV Reagent Program, cata-
log number 3418). S expression plasmids for SARS-CoV-2 VOCs were similarly
codon optimized and modified, and included the following mutations:
B.1.1.7 (69 to 70 del, Y144del, N501Y, A570D, D614G, P681H, T718I, S982A,
D1118H), B.1.351 (L18F, D80A, D215G, 241 to 243 del, K417N, E484K, N501Y,
D614G, A701V, E1195Q). Infectivity and neutralization titers were deter-
mined using ACE2-expressing HEK293 target cells (Integral Molecular) in a
semiautomated assay format using robotic liquid handling (Biomek NXp
Beckman Coulter). Virions pseudotyped with the vesicular stomatitis virus G
protein were used as a nonspecific control. Test sera were diluted 1:40 in
growth medium and serially diluted; then 25 μL per well was added to a
white 96-well plate. An equal volume of diluted PSV was added to each well,
and plates were incubated for 1 h at 37 °C. Target cells were added to each
well (40,000 cells per well), and plates were incubated for an additional 48 h.
Relative light units were measured with the EnVision Multimode Plate
Reader (Perkin-Elmer) using the Bright-Glo Luciferase Assay System (Prom-
ega). Neutralization dose–response curves were fitted by nonlinear regres-
sion using the LabKey Server. Final titers are reported as the reciprocal of the
serum dilution necessary to achieve 50% inhibition SARS-CoV-2 (ID50) or
90% inhibition for SARS-CoV-1 (ID90, 90% inhibitory dilution). Assay equiv-
alency was established by participation in the SARS-CoV-2 Neutralizing Assay
Concordance Survey run by the Virology Quality Assurance Program and
External Quality Assurance Program Oversite Laboratory at the Duke Human
Vaccine Institute.
Authentic SARS-CoV-2 wild-type neutralization assay. Authentic virus neu-
tralization was measured using SARS-CoV-2 (2019-nCoV/USA_WA1/2020
[WA1/2020]) obtained from the Centers for Disease Control and Prevention
and passaged once in Vero CCL81 cells (American Type Culture Collection,
ATCC). Rhesus sera were serially diluted and incubated with 100 focus-
forming units of SARS-CoV-2 for 1 h at 37 °C. Serum−virus mixtures were
added to Vero E6 cells in 96-well plates and incubated for 1 h at 37 °C. Cells
were overlaid with 1% (wt/vol) methylcellulose in Minimum Essential Me-
dium (MEM). After 30 h, cells were fixed with 4% paraformaldehyde in PBS
for 20 min at RT, and then washed and stained overnight at 4 °C with
1 μg/mL CR3022 antibody in PBS supplemented with 0.1% saponin and 0.1%
BSA. Cells were subsequently stained with horseradish peroxidase-conjugated
goat anti-human IgG for 2 h at RT. SARS-CoV-2−infected cell foci were visualized
with TrueBlue peroxidase substrate (KPL) and quantified using ImmunoSpot
microanalyzer (Cellular Technologies). Neutralization curves were generated
with Prism software (GraphPad Prism 8.0).
Authentic SARS-CoV-2 variant and SARS-CoV-1 neutralization assay. The
SARS-CoV-2 viruses WA1/2020, USA/CA_CDC_5574/2020 (B.1.1.7), and hCoV-
19/South Africa/KRISP-EC-K005321/2020 (B.1.351) were obtained from BEI
Resources (NIAID, NIH) and propagated for one passage using Vero-E6 cells.
Virus infectious titer was determined by an end-point dilution and cyto-
pathic effect (CPE) assay on Vero-E6 cells to standardize the input of the
different variants. In order to confirm that comparable amounts of the
variants were used, the antiviral activity of Remdesivir nucleoside was tested
against the different variants, and the 50% inhibition drug concentration
against each virus was within the range of single dilution. In brief, serum
samples were heat inactivated and subjected to successive threefold dilu-
tions starting from 1:50. Triplicates of each dilution were incubated with
SARS-CoV-2 at a multiplicity of infection of 0.1 in Eagle’s MEM with 7.5%
inactivated fetal calf serum for 1 h at 37 °C. Virus–antibody mixture was
transferred onto a monolayer of Vero-E6 cells grown overnight and incu-
bated for ∼70 h. CPE of viral infection was visually scored for each well in a
blinded fashion by two independent observers. Results were reported as
percentage of neutralization at a given sample dilution. A SARS-CoV-1 au-
thentic plaque reduction virus neutralization assay was performed similarly
to the method previously described (74) with the following modifications.
The starting dilution of serum was 1:5, and ∼100 plaque-forming units of
virus were used for virus/serum incubation. The overlay used after virus
adsorption was Dulbecco’s Modified Eagle Medium containing 2% fetal
bovine serum (FBS) and 20% methylcellulose. Plates were then incubated for
5 d, and, post crystal violet staining, the washing step utilized water. Plaques
were graded as follows: ∼25 plaques and/or 25% monolayer damage (MD)
(-/+); ∼50 plaques and/or 50% MD (+); ∼75 plaques and/or 75% MD (++);
∼100 plaques and/or 100% MD (+++). All negative control wells were solid
monolayers.
ADNP. Biotinylated SARS-CoV-2 prefusion stabilized S trimer was incubated
with yellow-green streptavidin-fluorescent beads (Molecular Probes) for 2 h
at 37 °C. Ten microliters of a 100-fold dilution of protein-coated beads was
incubated for 2 h at 37 °C with 100 μL of 8,100-fold diluted plasma samples before
addition of effector cells (50,000 cells per well). Fresh human PBMCs were used as
effector cells after red blood cell lysis with Ammonium-Chloride-Potassium (ACK)
lysing buffer (ThermoFisher Scientific). After 1 h incubation at 37 °C, cells were
washed, surface stained, and fixed with 4% formaldehyde solution (Tousimis),
and fluorescence was evaluated on an LSRII flow cytometer (BD Bioscience). An-
tibodies used for flow cytometry included anti-human CD3 AF700 (clone UCHT1),
anti-human CD14 APC-Cy7 (clone MϕP9) (BD Bioscience, San Jose, C), and anti-
human CD66b Pacific Blue (clone G10F5) (BioLegend). The phagocytic score was
calculated by multiplying the percentage of bead-positive neutrophils (SSC high,
CD3− CD14− CD66+) by the geometric mean of the fluorescence intensity of
bead-positive cells and dividing by 10,000.
ADCP. ADCP was measured as previously described (75). Briefly, biotinylated
SARS-CoV-1 or SARS-CoV-2 prefusion-stabilized S trimer was incubated with
red streptavidin-fluorescent beads (Molecular Probes) for 2 h at 37 °C. Ten
microliters of a 100-fold dilution of beads–protein was incubated for 2 h at
37 °C with 100 μL of 8,100-fold (SARS-CoV-2) or 900-fold (SARS-CoV-1) di-
luted plasma samples before addition of THP-1 cells (20,000 cells per well;
Millipore Sigma). After 19 h incubation at 37 °C, the cells were fixed with 2%
formaldehyde solution (Tousimis), and fluorescence was evaluated on an
LSRII flow cytometer (BD Bioscience). The phagocytic score was calculated by
multiplying the percentage of bead-positive cells by the geometric mean of
the fluorescence intensity of bead-positive cells and dividing by 10,000.
Opsonization. SARS-CoV-2 S-expressing expi293F cells were generated by
transfection with linearized plasmid (pcDNA3.1) encoding codon-optimized
full-length SARS-CoV-2 S protein matching the amino acid sequence of the
IL-CDC-IL1/2020 isolate (GenBank accession number MN988713). Stable
transfectants were single-cell sorted and selected to obtain a high-level S
surface expressing clone (293F-spike-S2A). SARS-CoV-2 S-expressing cells
were incubated with 200-fold diluted plasma samples for 30 min at 37 °C.
Cells were washed twice and stained with anti-human IgG PE, anti-human
IgM Alexa Fluor 647, and anti-human IgA FITC (Southern Biotech). Cells were
then fixed with 4% formaldehyde solution, and fluorescence was evaluated
on an LSRII flow cytometer (BD Bioscience).
ADCD. ADCD was adapted from methods described previously (76). Briefly,
SARS-CoV-2 S-expressing expi293F cells were incubated with 10-fold diluted,
heat-inactivated (56 °C for 30 min) plasma samples for 30 min at 37 °C. Cells
were washed twice and resuspended in Roswell Park Memorial Institute
(RPMI) 1640 medium containing 10% FBS (R10 media). During this time,
lyophilized guinea pig complement (CL4051, Cedarlane) was reconstituted in
1 mL of cold water and centrifuged for 5 min at 4 °C to remove aggregates.
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Cells were washed with PBS and resuspended in 200 μL of guinea pig com-
plement, which was prepared at a 1:50 dilution in Gelatin Veronal Buffer with
Ca2+ and Mg2+ (IBB-300X, Boston BioProducts). After incubation at 37 °C for
20 min, cells were washed in PBS 15 mM (ethylenedinitrilo)tetraacetic acid
(ThermoFisher Scientific) and stained with an anti-Guinea Pig Complement C3
FITC (polyclonal, ThermoFisher Scientific). Cells were then fixed with 4%
formaldehyde solution, and fluorescence was evaluated on an LSRII flow
cytometer (BD Bioscience).
Trogocytosis. Trogocytosis was measured using a previously described assay
(40). Briefly, SARS-CoV-2 S-expressing expi293F cells were stained with PKH26
(Sigma-Aldrich). Cells were then washed with and resuspended in R10 media.
Cells were then incubated with 200-fold diluted plasma samples for 30 min at
37 °C. Effector PBMCs were next added to the R10 media at an effector to target
cell ratio of 50:1 and then incubated for 5 h at 37 °C. After the incubation, cells
were washed, stained with live/dead aqua fixable cell stain (Life Technologies),
and CD14 APC-Cy7 (clone MϕP9) for 15 min at RT, washed again, and fixed with
4% formaldehyde (Tousimis) for 15 min at RT. Fluorescence was evaluated on an
LSRII flow cytometer (BD Bioscience). Trogocytosis was evaluated by measuring
the PKH26 mean fluorescence intensity of the live CD14+ cells.
Antigen-Specific T Cell Responses. Cryopreserved PBMCs were thawed and
rested for 6 h in R10 with 50 U/mL Benzonase Nuclease (Sigma-Aldrich). They
were then stimulated with peptide pools for 12 h. Stimulations consisted of
two pools of peptides spanning the S protein of SARS-CoV-2 or SARS-CoV-1 (1
μg/mL, JPT Peptide Technologies, PM-WCPV-S and PM-CVHSA-S, respectively)
in the presence of Brefeldin A (0.65 μL/mL, GolgiPlug, BD Cytofix/Cytoperm
Kit, catalog number 555028), costimulatory antibodies anti-CD28 (BD Bio-
sciences catalog number 555725; 1 μg/mL) and anti-CD49d (BD Biosciences
catalog number 555501; 1 μg/mL), and CD107a (H4A3, BD Biosciences cata-
log number 561348, lots 9143920 and 253441). Following stimulation, cells
were stained serially with LIVE/DEAD Fixable Blue Dead Cell Stain (Ther-
moFisher #L23105) and a mixture of fluorescent-labeled antibodies (BD
Biosciences unless otherwise indicated) to cell surface markers CD4-PE-Cy5.5
(S3.5, ThermoFisher #MHCD0418, lots 2118390 and 2247858), CD8-BV570
(RPA-T8, BioLegend #301038, lot B281322), CD45RA BUV395 (5H9, #552888,
lots 154382 and 259854), CD28 BUV737 (CD28.2, #612815, lot 0113886),
CCR7-BV650 (GO43H7, #353234, lots B297645 and B316676), and
HLA-DR-BV480 (G46-6, #566113, lot 0055314). Intracellular cytokine staining
was performed following fixation and permeabilization (BD Cytofix/Cyto-
perm, BD Biosciences) with CD3-Cy7APC (SP34-2, #557757, lots 6140803 and
121752), CD154-Cy7PE (24-31, BioLegend #310842, lots B264810 and
B313191), IFNγ-AF700 (B27, #506516, lots B187646 and B290145), TNFα-FITC
(MAb11, #554512, lot 15360), IL-2-BV750 (MQ1-17H12, BioLegend #566361,
lot 0042313), IL-4 BB700 (MP4-25D2, lots 0133487 and 0308726), MIP-1b-PE
(D21-1351, #550078, lot 9298609), CD69-ECD (TP1.55.3, Beckman Coulter
#6607110, lots 7620070 and 7620076), IL-21-AF647 (3A3-N2.1, #560493, lots
9199272 and 225901), IL-13-BV421 (JES10-5A2, #563580, lots 9322765,
210147, and 169570), and IL-17a-BV605 (BL168, BioLegend #512326, lot
B289357). Sample staining was measured on a FACSymphony A5 SORP
(Becton Dickenson), and data were analyzed using FlowJo v.9.9 software
(Tree Star, Inc.). CD4+ and CD8+ T cell subsets were pregated on memory
markers prior to assessing cytokine expression as follows: single positive or
double negative for CD45RA and CD28. Boolean combinations of cells
expressing one or more cytokines were used to assess the total S-specific
response of memory CD4+ or CD8+ T cells. Responses from the two-
peptide pools spanning SARS-CoV-2 S or SARS-CoV-1 S were summed. Dis-
play of multicomponent distributions was performed with SPICE v6.0 (NIH).
Total and sgmRNA Quantification. Quantitative reverse transcription PCR
(RT-qPCR) was carried out for sgmRNA and total viral load RNA quantification
from NP swab, BAL fluid, and saliva samples. Primers targeted the envelope
(E) gene of SARS-CoV-2 (SI Appendix, Table S2). RNA was extracted from
200 μL of specimen using the EZ1 DSP Virus kit (Qiagen) on the EZ1 Ad-
vanced XL instrument (Qiagen). Briefly, samples were lysed in 200 μL of ATL
buffer (Qiagen) and transferred to the Qiagen EZ1 for extraction. Bacte-
riophage MS2 (ATCC) was added to the RNA carrier and used as an
extraction control to monitor efficiency of RNA extraction and amplification
(77). Purified RNA was eluted in 90 μL of elution buffer (AVE). The RT-qPCR
amplification reactions were performed in separate wells of a 96-well Fast
plate for the three targets: sgmRNA, RNA viral load, and MS2 RNA using
10 μL of extracted material 0.72 μM of primers, 0.2 μM of probe and 1×
TaqPath 1-Step RT-qPCR (Life Technologies, Thermo Fisher Scientific, Inc.).
Amplification cycling conditions were 2 min at 25 °C, 15 min at 50 °C, 2 min
at 95 °C, and 45 cycles of 3 s at 94 °C and 30 s at 55 °C with fluorescence read
at 55 °C. An RNA transcript for the SARS-CoV-2 E gene was used as a cali-
bration standard. RNA copy values were extrapolated from the standard
curve and multiplied by 45 to obtain RNA copies per milliliter. A negative
control (PBS) and two positive controls, contrived using heat-inactivated
SARS-CoV-2 (ATCC, VR-1986HK), at 106 and 103 copies per mL, were
extracted and used to assess performance of both assays.
Histopathology. Formalin-fixed sections of lung tissue were evaluated by
light microscopy and IHC. Lungs were perfused with 10% neutral-buffered
formalin. Lung sections were processed routinely into paraffin wax, and
then sectioned at 5 μm, and resulting slides were stained with hematoxylin
and eosin. IHC was performed using the Dako Envision system (Dako Agilent
Pathology Solutions). Briefly, after deparaffinization, peroxidase blocking, and
antigen retrieval, sections were covered with a mouse monoclonal
anti-SARS-CoV nucleocapsid protein (#40143-MM05, Sino Biological) at a di-
lution of 1:4,000 and incubated at RT for 45 min. They were rinsed, and the
peroxidase-labeled polymer (secondary antibody) was applied for 30 min.
Slides were rinsed, and a brown chromogenic substrate 3,3′ diaminobenzidine
solution (Dako Agilent Pathology Solutions) was applied for 8 min. The
substrate–chromogen solution was rinsed off the slides, and slides were
counterstained with hematoxylin and rinsed. The sections were dehydrated,
cleared with Xyless, and then coverslipped. Tissue section slides were evalu-
ated by a board-certified veterinary anatomic pathologist who was blinded to
study group allocations. IHC was performed with Dako Envision. Three tissue
sections from each of the right and left lung lobes were used to evaluate the
lung pathology. The histopathology of each section was evaluated on a scale
of 0 to 5: 0, absent; 1, minimal (<10% of tissue section affected); 2, mild (11 to
25% of tissue section affected); 3, moderate (26 to 50% of tissue section af-
fected); 4, marked (51 to 75% affected); 5, severe (>75% of tissue section
affected). Sections were evaluated for edema, hyaline membranes, cellular
infiltrates, alveolar histiocytes, type II pneumocyte hyperplasia, interstitial
fibroplasia, bronchus-associated lymphoid tissue hyperplasia, bronchiolar de-
generation, megakaryocytes in capillaries, and thrombosis. The scores for all
six sections of each pathologic finding were combined to create the final score
(Type II pneumocyte hyperplasia [TIIPH] score) for individual animals.
Statistical Analysis. Primary immunogenicity outputs of binding and neu-
tralizing antibody titers as well as T cell responses were compared across
vaccination groups using the Kruskal−Wallis test. Nonparametric pair-wise
comparisons between groups were made using the post hoc Dunn’s test.
Statistical significance was preset at an alpha level of 0.05.
Data Availability. All study data are included in the article and SI Appendix.
Some study data are available upon request to K.M. or D.L.B.
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